Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
January 2015

Recent Stories of Interest

From Specialty Pharmacy News - Earlier this month, the U.S. pharmaceutical market moved a lot closer to welcoming the first drug approved through the biosimilar pathway when an FDA committee unanimously recommended its approval. And with an increasing number of biologics boasting price tags nearing — or exceeding — $100,000 per patient per year, biosimilars are expected to bring some relief to patients and payers alike. Read more

The Dec. 19 FDA approval of AbbVie Inc.’s Viekira Pak (ombitasvir, paritaprevir… Read more

Outrage over the prices of new hepatitis C therapies continues to mount,… Read more

With prices for biologics eating up more and more of payers’ budgets,… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

January 21, 2015
FDA OKs Novartis Psoriasis Therapy

FDA approves Novartis’ Cosentyx (secukinumab) for moderate-to-severe plaque psoriasis; drug is first IL-17A antagonist

January 21, 2015
ASCO Will Work With SAP to Develop CancerLinQ

ASCO is teaming with SAP in the development of CancerLinQ to create Big Data cancer platform; first version with data from 8 practices will be released later this year

January 5, 2015
ODAC Meeting Materials Look Positive for Sandoz Biosimilar

Ahead of Wednesday meeting, ODAC materials indicate Sandoz’s biosimilar filgrastim is “highly similar” to Amgen’s Neupogen

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?